Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2007
12/27/2007WO2007120284A3 Glucagon receptor antagonists, preparation and therapeutic uses
12/27/2007WO2007118325A8 Enhancement of memory and/or cognition using substituted butyrophenone compounds
12/27/2007WO2007117971A3 Ocular allergy treatments
12/27/2007WO2007117565A9 Standardization of processes for culturing primary cells
12/27/2007WO2007117559A8 Renin inhibitors
12/27/2007WO2007116395A3 Antisense oligonucleotides against acetylcholinesterase for treating inflammatory diseases
12/27/2007WO2007116230A8 Azetidine derivatives as g-protein coupled receptor (gpr119 ) agonists
12/27/2007WO2007116229A8 Heterocyclic gpcr agonists
12/27/2007WO2007115077A3 Bicyclic benzimidazole compounds and their use as metabotropic glutamate receptor potentiators
12/27/2007WO2007111720A3 Formulation of insoluble small molecule therapeutics in lipid-based carriers
12/27/2007WO2007110761A8 Polymorphic forms of olopatadine hydrochloride and methods for producing olopatadine and salts thereof
12/27/2007WO2007109812A3 Immunopotentiating compounds
12/27/2007WO2007109201A3 Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
12/27/2007WO2007106708A3 Combinations of the angiotensin ii antagonist valsartan and the nep inhibitor daglutril
12/27/2007WO2007106494A3 Methods and compositions for treatment of diastolic heart failure
12/27/2007WO2007103427A9 Medical use of bilirubin and its structural analogues
12/27/2007WO2007099402A3 New 3’-, 7-substituted indirubins and their applications
12/27/2007WO2007095250A3 Compositions and methods for inhibiting optic nerve damage
12/27/2007WO2007092779A3 Aripiprazole co-crystals
12/27/2007WO2007092751A3 Compounds and methods for modulating fx-receptors
12/27/2007WO2007092558A3 Sulfonamide derivatives to treat infection with hepatitis c virus
12/27/2007WO2007092435A3 11-beta hsd1 inhibitors
12/27/2007WO2007087462A3 Methods and compositions for cancer therapy using a novel adenovirus
12/27/2007WO2007085806A3 Therapeutic delivery of carbon monoxide
12/27/2007WO2007084964A3 Pharmaceutical composition comprising a protein pump inhibitor and protein component
12/27/2007WO2007084839A3 Dietary methods and compositions for enhancing metabolism and reducting reactive oxygen species
12/27/2007WO2007082292A3 Tri-substituted 2-benzhydryl-5-benzlamino-tetrahydro-pyran-4-ol and 6-benzhydryl-4-benzylamino-tetrahydro-pyran-3-ol analogues, and novel 3,6-disubstituted pyran derivatives
12/27/2007WO2007079560A3 Pharmaceutical compounds that contain nanoparticles useful for treating restenotic lesions
12/27/2007WO2007079389A3 Composition and method of use thereof
12/27/2007WO2007076415A3 Compositions and methods for preventing or reducing postoperative ileus and gastric stasis
12/27/2007WO2007076318A3 Camphor-derived cxcr3 antagonists
12/27/2007WO2007076140A3 Treatment methods employing histamine h3 receptor antagonists, including betahistine
12/27/2007WO2007074344A8 Use of alpha-hydroxy carbonyl compounds as reducing agents
12/27/2007WO2007072158A3 Pyrimidine derivatives for the treatment of abnormal cell growth
12/27/2007WO2007067508A3 Pharmaceutical formulation containing phenytoin sodium and magnesium stearate
12/27/2007WO2007066336A3 Chemical derivatives of jasmonate, pharmaceutical compositions and methods of use thereof
12/27/2007WO2007064978A3 Localized delivery of drug combinations
12/27/2007WO2007064968A3 Stable pharmaceutical compositions of 5,10 methylenetetrahydrofolate
12/27/2007WO2007062413A3 Use of parp-1 inhibitors
12/27/2007WO2007061820A3 Dissolution of arterial cholesterol plaques by a class of pharmacological compounds
12/27/2007WO2007059323A3 Certain chemical entities, compositions, and methods
12/27/2007WO2007059113A3 Certain chemical entities, compositions, and methods
12/27/2007WO2007058852A3 Inhibitors of akt activity
12/27/2007WO2007056219A3 [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto
12/27/2007WO2007056210A3 Diphenylmethane derivatives as inhibitors of leukotriene biosynthesis
12/27/2007WO2007052289A3 Novel dispersible tablet composition
12/27/2007WO2007047305A8 Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors
12/27/2007WO2007045593A3 Naphthyl derivatives as inhibitors of beta-amyloid aggregation
12/27/2007WO2007041398A3 Treatment of cancer with specific rxr agonists
12/27/2007WO2007036543A8 Beta-3-agonist use for treating kidney and bladder troubles of a patient with spinal cord damages
12/27/2007WO2007035755A3 Methods of treating hematological malignancies
12/27/2007WO2007020671A3 Ophthalmic compositions containing mucoadhesive polysaccharides able to promote corneal re-epithelization
12/27/2007WO2007014347A3 Method of treating a condition associated with phosphorylation of task-1
12/27/2007WO2007004072B1 Formulations and methods for treating amyloidosis
12/27/2007WO2007003933A3 Combination therapy of cancer with azd2171 and gemcitabine
12/27/2007WO2006131491A8 Polymorphs of ethyl 3-[(2-{[4-(hexyloxycarbonylamino-iminomethyl)phenylamino]methyl}-1-methyl-1h-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate
12/27/2007WO2006129181A3 Preparation of 4-pyrimidone derivatives for treating inflammatory diseases
12/27/2007WO2006129158B1 3 - indazolyl - isoxazoline derivatives as inhibitors of phosphodiesterase type - i
12/27/2007WO2006128142A8 Inhibitors of cytosolic phospholipase a2
12/27/2007WO2006124727A3 Compositions and methods useful in preventing cardiac hypertrophy
12/27/2007WO2006112694A8 Nutritional supplement with colostrum and epa or dha or gla
12/27/2007WO2006104975A3 Modulation of telomere length in telomerase positive cells and cancer therapy
12/27/2007WO2006076009A3 Transcription factor modulating compounds and methods of use thereof
12/27/2007WO2006052668A3 Induction of antigen specific immunologic tolerance
12/27/2007WO2005044200A3 Methods and compositions for treating mcp-1 related pathologies
12/27/2007WO2005030228A3 Use of a composition containing extracts of vitis vinifera and lycopersicum for protecting the skin
12/27/2007WO2005021009A3 Formulations and methods of treating inflammatory bowel disease
12/27/2007WO2004058735A3 Ligands of melanocortin receptors and compositions and methods related thereto
12/27/2007WO2002056823A3 Redox therapy for tumors
12/27/2007US20070299263 Hydroxy Alkyl Amines
12/27/2007US20070299139 Lyophilisate Comprising N-Diaminomethylene-2-Methyl-4,5-Di(Methylsulfonyl)Benzamide
12/27/2007US20070299138 Treating tumors by administering the octasodium salt of the tetrameric cyclic compound of 4,5-dihydroxynaphthalene-2,7, disulfonic acid linked by methylene bridges; inhibits the secretion of matrix metalloproteinase by endothelial cells
12/27/2007US20070299137 N-Acylated Derivatives Of Dicarboxylic Acids With Amino Acids And Vegetable Protein Hydrolsates And Their Use In Cosmetics And Pharmaceuticals
12/27/2007US20070299136 Crystalline and Amorphous Forms of Efaproxiral Sodium
12/27/2007US20070299135 Compositions for Use in Surgery
12/27/2007US20070299134 Concentrated and odorless omega 3 fatty acids
12/27/2007US20070299133 Concentrated omega-3 fatty acids and mixtures containing them
12/27/2007US20070299132 Stable Aqueous Formulation of a Platin Derivative
12/27/2007US20070299131 Furancarbonylguanidine Derivatives, Their Preparation and Pharmaceutical Compositions Containing Them
12/27/2007US20070299130 Benzopyran Compound
12/27/2007US20070299129 Compounds and derivatives for the treatment of medical conditions by modulating hormone-sensitive lipase activity
12/27/2007US20070299128 Use of Tryptophan Derivatives for the Specific Cytostatic Treatment of Serotonin-Producing Tumors
12/27/2007US20070299127 Compositions and kits comprising a melatonin component and an omega-3-fatty acid component
12/27/2007US20070299126 Substituted pyrrole-indoles
12/27/2007US20070299125 Substituted indoles
12/27/2007US20070299124 Formulations and methods for treating dry eye
12/27/2007US20070299123 Amorphous frovatriptan succinate and process for the preparation thereof
12/27/2007US20070299122 Method of Treating Pathological Blushing
12/27/2007US20070299121 administering sublingually to a horse a semisolid transmucosal gel containing detomidine, hydroxypropyl cellulose, sodium lauryl sulfate, propylene glycol and water for providing sedation and analgesia; rapid onset of action, low irritation potential in the oral mucosa
12/27/2007US20070299120 1 -(Methylsulfonylamino)-3 - [2-(4-methoxyphenyl)ethyl]-4-(4-methoxyphenyl) -2-imidazolidinone; atrial-selective antiarrhythmic agents; cardiovascular disorders; arrhytmia, atrial fibrillation, atrial flutter, thromboembolism, stroke, and heart failure
12/27/2007US20070299119 Prophylactic or Therapeutic Agent for Severe Diabetic Retinopathy
12/27/2007US20070299118 Benzoxazolone Derivatives, Processes For Preparing Them And Their Uses
12/27/2007US20070299117 Hydroxypropylaimines
12/27/2007US20070299116 Human protein tyrosine phosphatase inhibitors and methods of use
12/27/2007US20070299114 Biaryl Derivatives
12/27/2007US20070299113 Metabotropic glutamate receptor modulators
12/27/2007US20070299112 Substituted thienopyrrole carboxylic acid amides, pyrrolothiazole carboxylic acid amides, and related analogs as inhibitors of casein kinase i
12/27/2007US20070299111 Benzamide derivatives and uses related thereto
12/27/2007US20070299110 Novel Tetrazole Derivatives as Positive Allosteric Modulators of Metabotropic Glutamate
12/27/2007US20070299109 Dimeric Compounds Of Piperidine, Piperazine Or Morpholine Or Their 7-Membered Analogs Suitable For The Treatment Of Neurodegenerative Disorders
1 ... 3441 3442 3443 3444 3445 3446 3447 3448 3449 3450 3451 3452 3453 3454 3455 3456 3457 3458 3459 3460 3461 ... 7860